Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.

NCT ID: NCT06843707

Last Updated: 2025-02-25

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 2500 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-01-01
• Study Completion Date: 2027-12-31

Brief Summary

This study will utilize tissue and peripheral blood samples for metabolomics analysis and establish a longitudinal metabolomics cohort at multiple critical treatment time points to comprehensively investigate the role of metabolomics in the diagnosis, prognosis, and therapeutic monitoring of lung cancer. By profiling metabolic alterations, this study aims to identify potential biomarkers for distinguishing benign and malignant lung nodules, predicting therapeutic efficacy, and assessing long-term prognosis. Key time points include initial screening for lung nodules, postoperative evaluation to predict treatment outcomes, and therapeutic monitoring to assess efficacy after medication or other interventions. Through these analyses, the study seeks to uncover underlying metabolic mechanisms and provide valuable insights into personalized lung cancer management.

Conditions

Lung Cancer; Lung; Lung Cancer (NSCLC); Metabolomics

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Interventions

Monitoring serum metabolites in lung cancer patients using tissue and peripheral blood samples.

This study focuses on monitoring serum metabolites in lung cancer patients by utilizing tissue and peripheral blood samples. By analyzing the metabolic profiles of serum, the research aims to identify significant metabolic alterations associated with lung cancer progression, treatment response, and overall prognosis. The study seeks to provide a comprehensive understanding of how metabolic changes in serum reflect disease dynamics and therapeutic outcomes, ultimately contributing to the development of more accurate diagnostic and prognostic biomarkers for lung cancer management.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Signing of the informed consent form;

2. Male or female, aged 18-75 years;

3. Patients with lung nodules confirmed by CT examination;

4. Good preoperative pulmonary function cooperation and complete reporting;

5. Preoperative chest single/dual phase CT scans without significant artefacts and with complete imaging;

6. The interval between preoperative pulmonary function and single/dual phase CT scans does not exceed one month.

Exclusion Criteria

1. Poor preoperative pulmonary function cooperation or missing reports;

2. Preoperative chest single/dual phase CT scans exhibit significant artefacts or image omission;

3. The interval between preoperative pulmonary function and single/dual phase CT scans exceeds one month;

4. Complication with severe respiratory disorders (such as lung transplantation, pneumothorax, giant bullae, etc.);

5. Coexisting with other severe functional impairments;

6. Patients with obstructive lesions such as airway or esophageal stenosis;

(8) Medication use before pulmonary function testing that does not meet the cessation guidelines; (9) Pulmonary function report quality graded D-F.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The First Affiliated Hospital of Guangzhou Medical University

OTHER

Sponsor Role: lead

Responsible Party

Jianxing He

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

the First Affiliated of Guangzhou Medical University

Guangzhou, Guangdong, China

Site Status: RECRUITING

Countries

China

Central Contacts

Jianxing He, Professer

Role: CONTACT

drjiaxing.he@gmail.com

86-20-83337792

Other Identifiers

2025-01-12

Identifier Type: OTHER

Identifier Source: secondary_id

LungMet

Identifier Type: -

Identifier Source: org_study_id